Friday, 16 June 2017 507 aerofaciens had a complete opposite effect. Suppression of arthritis by P histicola was dependent on an increase in the numbers of CD103+ dendritic cells, myeloid suppressors, CD11b+Gr-1, and T regulatory cells, CD4+CD25+FoxP3+, in the gut as well as systemically. Background: Rheumatoid arthritis is an autoimmune disease characterized by altered cellular homeostasis. A great role of an autophagy is expected in the pathogenesis of these changes. Objectives: To assess the functional activity of AMFK as a strategic biopower regulator of an autophagy and specific indicator of red-ox potential of cells in the sinovial fluid (SF) of patients with rheumatoid arthritis (RA). Methods: SF of knee joints of 7 RA patients with active synovitis and 5 donors were investigated. Activity of enzymes was measured in cytosol of SF cells after ultracentrifugation. Activity of AMFK was estimated with the Western blotting method. The consumption speed of oxygen by SF cells was recorded polarographycally using as the substrate glutamic acid (5 μ mol/ml in incubation fluid). Registration of the active forms of oxygen was carried out by EPR (electronic paramagnetic resonance). Levels of adenylic nucleotides were determined chromatographically.
FRI0079 TAS5315, A NOVEL BRUTON'S TYROSINE KINASE INHIBITOR, IMPROVE BONE MINERAL DENSITY (BMD) AND BONE EROSION VIA INHIBITION OF OSTEOCLAST ACTIVATION IN MURINE MODEL FOR RHEUMATOID ARTHRITIS
Y. Yoshiga, F. Hosoi, S. Iguchi, R. Kaneko, Y. Nakachi, D. Akasaka, K. Tanaka, K. Yonekura, T. Utsugi, E. Sasaki, Y. Iwasawa. Taiho Pharmaceutical, Ibaraki, Japan Background: The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome 1 . Although several anti-inflammatory drugs improve symptoms of articular inflammation, they are less effective against bone erosion. The bone erosions in RA are associated with aberrant activations of osteoclasts induced by pro-inflammatory cytokines and receptor activator of nuclear factor κB ligand (RANKL) 2 . Bruton's tyrosine kinase (BTK), which is expressed in immune cells and mature osteoclast, is reported to be a key molecule in inflammatory response and bone resorption 3, 4 . Thus, targeting BTK may be efficacious against not only inflammation but also bone erosion through direct regulation of activation of effector cells such as B cells, macrophages and osteoclasts in RA. Objectives: In this study, we evaluated the effect of TAS5315, a novel BTK inhibitor, on in vitro osteoclasts activation and bone erosion in mouse collageninduced arthritis. Methods: Kinase selectivity of TAS5315 was assessed by available kinase Abstract FRI0078 -Table 1 AMPK activity (units/mg of protein), oxygen uptake rate (OUR, natoms of oxygen/min/mg of protein), the level of active free radical form of oxygen (AFRF, units/mg of protein), the content of adenine nucleotides in SF (nmol/ml) and pH in SF in RA assay panels. The effects of TAS5315 on macrophages and osteoclasts were assessed by examining phosphorylation of BTK, cytokine productions, osteoclast differentiation and bone resorptions. The effects of TAS5315 were investigated in mouse collagen-induced arthritis (CIA). Disease severity was evaluated by clinical score of paw swelling. Changes in bone mineral density (BMD) and bone erosion were assessed using microCT. TNF blocker was used as a control drug. Results: TAS5315 selectively inhibited the enzyme activity of BTK and had less off target inhibition against other kinases. TAS5315 dose-dependently inhibited cytokine productions by macrophages, phosphorylation of BTK, osteoclastogenesis and bone resorbing activity in osteoclasts. In established mouse CIA, TAS5315 significantly ameliorated paw swelling in a dose dependent manner and the anti-inflammatory effect of TAS5315 (0.3 mg/kg, once daily) was comparable to that of TNF blocker. Most importantly, improvement of BMD and bone erosion were observed in TAS5315 treated mice at a doses of higher than 0.1 mg/kg within 13 days from treatment initiation, but not in TNF blocker-treated mice. The onset of action of TAS5315 on BMD and bone erosion was earlier and stronger compared with that of TNF blocker. These data suggest that TAS5315 had direct effect against osteoclasts function and led to improvement of bone erosion in murine model for RA. Conclusions: Our study demonstrates that TAS5315, a novel BTK inhibitor, would be an ideal RA therapeutic agent that could inhibit bone destruction as well as inflammation. 
Methods:
We assessed the severity of zymosan A-induced ILD in SKG mice histologically, and examined lung-infiltrating cells by Giemsa stain and flow cytometry. Total lung cells and isolated monocytic myeloid-derived suppressor cells (M-MDSCs) were cultured in vitro with GM-CSF (and IL-4). The proliferation of CSFE-labeled naïve T cells co-cultured with isolated CD11b + Gr1 dim cells and MDSCs was evaluated by flow cytometry. Results: MDSCs, Th17 cells, and group 1 and 3 innate lymphoid cells (ILC1s and ILC3s) were increased in the lungs; the proportion of these cells varied with ILD severity. In this process, we found that a unique cell population, CD11b + Gr1 dim cells, were expanded in the severely inflamed lungs (Figure) . About half of the CD11b + Gr1 dim cells expressed CD11c and Giemsa stain revealed that they were morphologically dendritic cell (DC)-like. The CD11b + Gr1 dim cells were induced from M-MDSCs with GM-CSF in vitro and were considered tolerogenic because they expressed high levels of PD-L1 and suppressed T-cell proliferation. 
